Novartis Q4 Results

↓ Content Click below to navigate through the document Our pipeline projects at a glance ↑ Company overview INNOVATION Financial review Phase 1/2 Phase 3 Registration Total Conclusions Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical trials Abbreviations References Oncology Solid tumors Hematology Immunology Neuroscience 25 12 3 40 18 6 3 27 7 6 0 13 17 10 1 28 5 5 0 10 Cardiovascular, Renal and Metabolic 6 10 0 16 Others (thereof IB&GH) 11 (7) 4 (3) 0 15 64 41 4 109 IB&GH: In-market Brands and Global Health. □ NOVARTIS Reimagining Medicine Novartis Q4 Results | January 31, 2024 37

View entire presentation